Skip to main content
TRLVTrulieve Cannabis Corp. SubordiHold5.6·$9.51-0.94%
HoldModerate Confidence
Investment thesis

TRLV cannot be traded this run due to a missing price feed, and beneath that data gap sits a mixed picture: a consistent earnings beat streak and strong Piotroski quality offset by margin-compression value-trap signals and declining revenue.

Thesis pillars

  • Value Trap Margin CompressionDeteriorating
  • Strong Piotroski Cash QualityStable
  • Declining Revenue TrendDeteriorating
  • +2 more pillars — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Trulieve Cannabis Corp. Subordi (TRLV) Stock Analysis

Inst Constrain edge

HoldVALUE-TRAP 1/5ValueGrowthModerate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Hold if already holding. Not a fresh buy at $9.51, but acceptable to hold if already in. Reason: mixed signals — some dimensions strong, others weak.

Trulieve Cannabis Corp. is a vertically integrated, multi-state cannabis operator headquartered in Tallahassee, Florida, describing itself as the largest cannabis retailer in the United States with market-leading positions in Arizona, Florida, Georgia, Pennsylvania, and West... Read more

QualityF-score8 / 9FCF yield12.56%
Stop $8.88Target $15.82(analyst − 13%)A.R:R 4.4:1
Analyst target$18.18+91.2%7 analysts
$15.82our TP
$9.51price
$18.18mean
$21

Hold if already holding. Not a fresh buy at $9.51, but acceptable to hold if already in. Reason: mixed signals — some dimensions strong, others weak. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Score 5.6/10, moderate confidence.

Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news boost analyst 0.40, earnings proximity 82d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.

10-K grounded · weekly refresh

About Trulieve Cannabis Corp. Subordi

About Trulieve Cannabis Corp. Subordi

Trulieve operates 233 dispensaries and 15 cultivation and processing facilities across nine U.S. states as of December 31, 2025, anchored by market-leading positions in Florida, Pennsylvania, and Arizona that the company organizes into three regional hubs: Southeast, Northeast, and Southwest. Florida alone accounts for 162 of the company's dispensaries and five of its 15 cultivation and processing facilities, including a 750,000-square-foot automated indoor cultivation facility.

Trulieve earns revenue by cultivating, processing, and retailing its own branded cannabis products — premium tier brands including Avenue, Cultivar Collection, and Muse alongside value-tier brands Co2lors and Roll One — supplemented by partner brands such as Alien Labs, Khalifa Kush, and Seed Junky sold through more than 200 of its retail locations. In Florida and Georgia the company is fully vertically integrated from cultivation through retail, while in Arizona, Maryland, Pennsylvania, and West Virginia it has achieved varying degrees of vertical integration to support wholesale and retail operations. In December 2025, Trulieve redeemed the full $368.0 million principal of its 8.0% Senior Secured Notes due 2026 and issued $140.0 million of new 10.5% Senior Secured Notes due 2030, followed by a $60.0 million second tranche in January 2026, refinancing its balance sheet as it also pursues a conditional Texas Dispensing Organization license awarded in December 2025.

Show full overview

Trulieve's business remains legally exposed at the federal level: cannabis is classified as a Schedule I controlled substance under the Controlled Substances Act even though, as of December 31, 2025, adult-use cannabis is legal in 24 states plus the District of Columbia, Guam, the Northern Mariana Islands, and the U.S. Virgin Islands. On December 18, 2025, President Trump signed an Executive Order directing the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the CSA in the most expeditious manner, a change that, if finalized, would ease the tax and banking constraints tied to Schedule I status but remains subject to completion of a formal rulemaking process with no fixed deadline.

See also: Healthcare · Drug Manufacturers - Specialty & Generic

From Trulieve Cannabis Corp. Subordi's most recent 10-K filing, extracted July 6, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-08-14
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Nov 5, 202682d to earnings· next earnings call

Thesis

Rewards
Attractive valuation
Analyst upside: 66%
Recent Analyst detected in news
Risks
No bear case signals

Key Metrics

P/E (TTM)
P/E (Fwd)22.9
Mkt Cap$1.8B
EV/EBITDA7.0
Profit Mgn-41.6%
ROE-47.7%
Rev Growth-10.3%
Beta1.72
DividendNone
Rating analysts13

Quality Signals

Piotroski F8/9

Options Flow

P/C2.50bearish
IV91%elevated

Material Events(8-K, last 90d)

  • 2026-07-02Item 5.02MEDIUM
    Trulieve eliminated the stand-alone Chief Accounting Officer position and terminated Brett Walsh without cause, effective June 30, 2026; CFO Jan Reese was appointed principal accounting officer with no compensation adjustment.
    SEC filing →
  • 2026-06-12Item 5.02MEDIUM
    President Jason Pernell mutually agreed to terminate his employment with Trulieve effective June 11, 2026, entering a Separation Agreement with a mutual release and a one-year equity lock-up. No successor named in the disclosed text.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Bollinger
0.3
Support Resistance
1.7
52w Position
5.5

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
0.4
Growth Rank
0.5
Value Rank
6.9
GatesExecutive change: officer departure/appointmentMomentum 5.8>=5.5A.R:R 4.4 ≥ 1.5Insider activity: OKNEWS BOOST ANALYST 0.40EARNINGS PROXIMITY 82d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
66 · Neutral
20D MA 50D MA 200D MASupport $7.82Resistance $9.90

Price Targets

$9
$16
A.Upside+65.7%
A.R:R4.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Analyst Consensus

Analysts13
Consensus4.1/5
Avg Target$18

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-11-05 (82d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is TRLV stock a buy right now?

Hold if already holding. Not a fresh buy at $9.51, but acceptable to hold if already in. Reason: mixed signals — some dimensions strong, others weak. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Target $15.82 (+66.4%), stop $8.88 (−7.1%), A.R:R 4.4:1. Score 5.6/10, moderate confidence.

What is the TRLV stock price target?

Take-profit target: $15.82 (+65.7% upside). Target $15.82 (+66.4%), stop $8.88 (−7.1%), A.R:R 4.4:1. Stop-loss: $8.88.

Is TRLV overvalued or undervalued?

Trulieve Cannabis Corp. Subordi trades at a P/E of N/A (forward 22.9). TrendMatrix value score: 8.3/10. Verdict: Hold.

What do analysts say about TRLV?

13 analysts cover TRLV with a consensus score of 4.1/5. Average price target: $18.

What does Trulieve Cannabis Corp. Subordi do?Trulieve Cannabis Corp. is a vertically integrated, multi-state cannabis operator headquartered in Tallahassee,...

Trulieve Cannabis Corp. is a vertically integrated, multi-state cannabis operator headquartered in Tallahassee, Florida, describing itself as the largest cannabis retailer in the United States with market-leading positions in Arizona, Florida, Georgia, Pennsylvania, and West Virginia. As of December 31, 2025, the company operated 233 dispensaries and 15 cultivation and processing facilities across nine states, organized into three regional hubs, selling owned brands such as Avenue, Cultivar Collection, and Muse alongside partner brands to medical and adult-use cannabis customers.

Related stocks: BCRX (BioCryst Pharmaceuticals, Inc.) · IRWD (Ironwood Pharmaceuticals, Inc.) · NBIX (Neurocrine Biosciences, Inc.) · ANIP (ANI Pharmaceuticals, Inc.) · BHC (Bausch Health Companies Inc.)
Home Stocks TRLV

Latest news

Latest News

TradingKey16d ago
NewsBreak: Local News & Alerts9d agoRestructuring
TipRanks9d ago
Ca.finance.yahoo.com9d ago
Finance.yahoo.com9d ago
Newswire Canada9d ago
PR Newswire9d ago
Yahoo Finance9d ago
MarketBeat9d ago
富途牛牛11d agoEarnings
MarketBeat8d ago
TradingKey18d ago
TradingKey18d ago
Investing.com18d ago
TradingKey14d ago
Tradingkey.com14d ago
Finance.biggo.com7d ago
Yahoo Finance7d agoEarnings
TipRanks7d agoEarnings
GuruFocus7d ago
Loading more...